Clinical Trials Browser

Completed × Has results × pevonedistat × Clear all

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04266795 2025-10-21

PEVENAZA

Phase 2 Completed

164 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03770260 2025-06-19

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

Phase 1 Completed

8 enrolled 11 charts

Plasma cell

Multiple Myeloma

NCT03813147 2025-04-13

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

12 enrolled 16 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03323034 2024-10-22

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Phase 1 Completed

30 enrolled 19 charts

CNSLymphoid

Lymphoma, Central Nervous System Neoplasms

NCT03814005 2024-09-05

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Phase 1 Completed

17 enrolled 33 charts

MyeloidOther hematologic neoplasm

Liver Diseases, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Renal Insufficiency

NCT02782468 2023-11-03

A Study of Pevonedistat in Adult East Asian Participants

Phase 1 Completed

23 enrolled 23 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03330106 2023-03-28

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

Phase 1 Completed

68 enrolled 18 charts

Advanced Solid Neoplasm

NCT02610777 2022-09-19

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Phase 2 Completed

120 enrolled 39 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03486314 2022-04-18

A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors

Phase 1 Completed

20 enrolled 18 charts

Advanced Solid Neoplasm

NCT01862328 2020-06-22

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

Phase 1 Completed

64 enrolled 21 charts

Other solid neoplasm

Solid Tumors

NCT01814826 2020-03-03

Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

Phase 1 Completed

64 enrolled 38 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03057366 2019-11-18

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

Phase 1 Completed

8 enrolled 26 charts

Tumor-Agnostic

Neoplasms

NCT02122770 2019-01-07

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

Phase 1 Completed

51 enrolled 30 charts

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

PANTHER

PEVENAZA

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

A Study of Pevonedistat in Adult East Asian Participants

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors